High-dose methotrexate dosing strategy in primary central nervous system lymphoma

References

• Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35(21):2410–2418.
   PubMed Web of Science ®Google Scholar
• Korfel A, Schlegel U. Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol. 2013;9(6):317–327.
   PubMed Web of Science ®Google Scholar
• Siegal T, Bairey O. Primary CNS lymphoma in the elderly: the challenge. Acta Haematol. 2019;141(3):138–145.
   PubMed Web of Science ®Google Scholar
• Han S, Wang M, Liu B, et al. Pemetrexed for primary central nervous system lymphoma in the elderly. Clin Transl Oncol. 2016;18(2):138–143.
   PubMed Web of Science ®Google Scholar
• Graham MS, DeAngelis LM. Improving outcomes in primary CNS lymphoma. Best Pract Res Clin Haematol. 2018;31(3):262–269.
   PubMed Web of Science ®Google Scholar
• Ney DE, Reiner AS, Panageas KS, et al. Characteristics and outcomes of elderly patients with primary central nervous system lymphoma: the memorial Sloan–Kettering Cancer Center experience. Cancer. 2010;116(19):4605–4612.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents. Hematology Am Soc Hematol Educ Program. 2017;2017(1):565–577.
   PubMed Web of Science ®Google Scholar
• O'Brien PC, Roos DE, Pratt G, Trans-Tasman Radiation Oncology Group, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a phase II multicenter study (Trans-Tasman radiation oncology group). Int J Radiat Oncol Biol Phys. 2006;64(2):408–413.
   PubMed Web of Science ®Google Scholar
• Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16(3):859–863.
   PubMed Web of Science ®Google Scholar
• Glass J, Gruber ML, Cher L, et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994;81(2):188–195.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, International Extranodal Lymphoma Study Group (IELSG), et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700):1512–1520.
   PubMed Web of Science ®Google Scholar
• Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003;21(6):1044–1049.
   PubMed Web of Science ®Google Scholar
• Omuro A, Chinot O, Taillandier L, et al. Hoang-Xuan K. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol. 2015;2(6):e251-9–e259.
   PubMed Web of Science ®Google Scholar
• Reni M, Ferreri AJ, Guha-Thakurta N, et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary Central nervous system lymphomas treated with upfront high-dose methotrexate. Int J Radiat Oncol Biol Phys. 2001;51(2):419–425.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Hader C, et al. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Ann Oncol. 2011;22(9):2080–2085.
   PubMed Web of Science ®Google Scholar
• Fox CP, Phillips EH, Smith J, British Society for Haematology, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184(3):348–363.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Central nervous system cancers (version 2.2020) [cited 2020 Aug 16]. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf.
   Google Scholar
• Ng S, Rosenthal MA, Ashley D, et al. High-dose methotrexate for primary CNS lymphoma in the elderly. Neuro Oncol. 2000;2(1):40–44.
   PubMed Web of Science ®Google Scholar
• Zhu JJ, Gerstner ER, Engler DA, et al. High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol. 2009;11(2):211–215.
   PubMed Web of Science ®Google Scholar
• Gaviani P, Simonetti G, Innocenti A, et al. Safety and efficacy of primary central nervous system lymphoma treatment in elderly population. Neurol Sci. 2016;37(1):131–133.
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010;12(7):736–744.
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Ambady P, Abdelaziz A, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83(3):235–239.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Cwynarski K, Pulczynski E, International Extranodal Lymphoma Study Group (IELSG), et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-27–e227.
   PubMed Web of Science ®Google Scholar
• Schorb E, Fox CP, Kasenda B, et al. Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. Br J Haematol. 2020;189(5):879–887.
   PubMed Web of Science ®Google Scholar
• Bromberg JEC, Issa S, Bakunina K, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20(2):216–228.
   PubMed Web of Science ®Google Scholar
• Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846–852.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (alliance 50202). J Clin Oncol. 2013;31(25):3061–3068.
   PubMed Web of Science ®Google Scholar
• Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol. 2015;26(7):1305–1313.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Hoang-Xuan K, Taillandier L, Chinot O, European Organization for Research and Treatment of Cancer Brain Tumor Group, et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the european organization for research and treatment of cancer brain tumor group. J Clin Oncol. 2003;21(14):2726–2731.
   PubMed Web of Science ®Google Scholar
• May J, Carson KR, Butler S, et al. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma. 2014;55(6):1345–1349.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E. MATRIX induction followed by autologous stem cell transplant or whole-brain irradiation in primary CNS lymphoma. 7-year results of the IELSG32 randomized trial. Abstract 047_16th ICML. Haemat Oncol. 2021;39(Supp 2):87–89.
   Google Scholar
• Vu K, Mannis G, Hwang J, et al. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019;186(1):180–183.
   PubMed Web of Science ®Google Scholar